This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Singh, B. Articles by Majeed-Saidan, M. Search for Related Content PubMed PubMed Citation Articles by Singh, B. Articles by Majeed-Saidan, M. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB CARBAMAZEPINE Medline Plus Health Information Seizures Social Bookmarking                   What's this?

Treatment of Neonatal Seizures With Carbamazepine

Division of Pediatric Neurology, Department of Neurology The University of Texas Southwestern Medical Center, Dallas, Texas

Poonam Singh, MD

Department of Pediatrics Armed Forces Hospital, Riyadh, Saudi Arabia

Ibrahim Al Hifzi, MD

Department of Pediatrics Armed Forces Hospital, Riyadh, Saudi Arabia

Masood Khan, MD

Department of Pediatrics Armed Forces Hospital, Riyadh, Saudi Arabia

Mohammed Majeed-Saidan, MD

Department of Pediatrics Armed Forces Hospital, Riyadh, Saudi Arabia

Carbamazepine has been used in adults and children for over 30 years. In spite of an excellent therapeutic and side-effect profile in older children, it has never been used as a primary anticonvulsant in neonates. This is the first report of the long-term use of carbamazepine in neonates. Ten full-term neonates with two or more seizures due to hypoxic-ischemic encephalopathy were given 10 mg/kg of carbamazepine as a loading dose via nasogastric tube. Twenty-four hours later, the first five patients began a maintenance regimen of 21 mg/kg/daily, and the remaining five patients began a maintenance regimen of 15 mg/kg/daily, all via nasogastric tube. Therapy was continued for 3 to 9 months. Drug levels were monitored every 2 to 4 hours during the first 24 hours, and on days 2, 4, 8, 15, 30, 45, and 60, and monthly thereafter. Absorption of carbamazepine was excellent even in sick neonates. Therapeutic levels were reached in 2 to 4 hours in all patients. Peak levels were achieved in 4 to 16 hours (mean, 9.2 ± 4.2). Elimination half-life was 24.5 hours. Levels dropped precipitously around 8 to 15 days and thereafter declined slowly over the next 3 months. Seizure control was excellent; only two patients had one seizure each during the first 10 hours. There were no gastrointestinal, hepatic, hematologic, renal, or dermatologic side effects. This preliminary study shows that carbamazepine may be an effective anticonvulsant for neonatal seizures. (J Child Neurol 1996;11:378-382).

Journal of Child Neurology, Vol. 11, No. 5, 378-382 (1996)
DOI: 10.1177/088307389601100506


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				J. J. Riviello Jr Pharmacology Review: Drug Therapy for Neonatal Seizures: Part 2 NeoReviews, June 1, 2004; 5(6): e262 - e268. [Full Text] [PDF]

				H. Nakamura, N. Torimoto, I. Ishii, N. Ariyoshi, H. Nakasa, S. Ohmori, and M. Kitada CYP3A4 and CYP3A7-Mediated Carbamazepine 10,11-Epoxidation Are Activated by Differential Endogenous Steroids Drug Metab. Dispos., April 1, 2003; 31(4): 432 - 438. [Abstract] [Full Text] [PDF]